midpage
Novartis Pharmaceuticals Corporation v. Nanjing Noratech Pharmaceutical Co., Ltd.
23-2317
| Fed. Cir. | Mar 11, 2025
Case Information

*1 Before L OURIE , T ARANTO , and S TOLL , Circuit Judges .

P ER C URIAM . O R D E R *2 Case: 23-2317 Document: 25 Page: 2 Filed: 03/11/2025 2 IN RE : ENTRESTO ( SACUBITRIL / VALSARTAN )

Upon consideration of appellant’s motion to stay the fi- nal judgment pending appeal, appellee’s motion to dismiss, the parties’ joint statement that if the invalidity judgment in Appeal No. 2023-2218 “is not affirmed,” “the judgment in this case should be vacated and the case remanded for further proceedings,” ECF No. 9 at 3, and this court’s re- cent decisions and orders in Appeal No. 2023-2218 revers- ing the relevant aspect of the judgment and enjoining the defendants in that case from launching their generic drug until issuance of mandate in that appeal,

I T I S O RDERED T HAT : (1) The district court’s judgment is vacated and the

cases remanded to the district court for further proceed- ings.

(2) The district court’s judgment is stayed until issu- ance of mandate in Appeal Nos. 2023-2317, 2023-2319. (3) Any pending motion otherwise is denied. (4) Each party shall bear its own costs.

F OR THE C OURT March 11, 2025 Date

AI-generated responses must be verified and are not legal advice.